DNB Carnegie analyst Ulrik Trattner upgraded Xvivo Perfusion (XVIPF) to Buy from Hold with a SEK 330 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XVIPF:
- XVIVO Perfusion AB Reports Mixed Results Amid Strategic Growth
- Xvivo Perfusion AB Faces Sales Decline Amid Strategic Investments in H1 2025
- XVIVO Perfusion AB Schedules Conference Call for Q2 2025 Interim Report
- XVIPF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- XVIVO Perfusion AB Wins 2025 SACC-USA Business Award for U.S. Market Growth